Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii-assisted standard bismuth quadruple therapy for Helicobacter pylori infection
ChiCTR2600123337Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Apr 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of saccharomyces boulardii in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoint: Helicobacter pylori eradication rate. Started Apr 2026; status: recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600123337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123337.